Levacetylleucine is under clinical development by IntraBio and currently in Phase II for Tay-Sachs Disease. According to GlobalData, Phase II drugs for Tay-Sachs Disease does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Levacetylleucine LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Levacetylleucine overview
Acetylleucine (Aqneursa) acts as anti neurological agent. it is formulated as suspension for oral route of administration. Aqneursa is indicated for the treatment of neurological manifestations of niemann-pick disease Type C (NPC) In adults and pediatric patients weighing ≥15 Kg.
Acetylleucine (IB-1001) is under development for the treatment of Niemann-Pick disease type C, GM1 Gangliosidosis, GM2 gangliosidosis, ataxia telangiectasia, spinocerebellar ataxia, Tay-Sachs Disease, multiple systems atrophy and Sandhoff disease. It is administered orally as powder for suspension.
It was under development for Lewy body dementia and frontotemporal dementia, Niemann-Pick disease type A and B and Alzheimer's Disease.
IntraBio overview
IntraBio is a private pharmaceutical company that focuses on the development and commercialization of novel and repurposed drugs to treat common and rare neurodegenerative diseases, including lysosomal storage disorders. The company is headquartered in Oxford, Oxfordshire, the UK.
For a complete picture of Levacetylleucine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
